SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Defining “Innovativeness” in Drug Development: A Systematic Review
16 references·0 citing·52 second hop
Defining “Innovativeness” in Drug Development: A Systematic Review (2013)Defining “Innovativeness” in Drug Develop…Evergreening, patent challenges, and effective market life in pharmaceuticals (2012)Evergreening, patent challeng…What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation? (2011)What Are The Respective Roles…The impact of global and local cohesion on innovation in the pharmaceutical industry (2011)The impact of global and loca…Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Pharmaceutical Innovation in …Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003 (2006)The Quantity And Quality Of W…Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases (2006)Adopting Orphan Drugs — Two D…Macro trends in pharmaceutical innovation (2005)Macro trends in pharmaceutica…“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada (2005)“Breakthrough” drugs and grow…Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Market Size in Innovation: Th…Physicians’ Views Of The Relative Importance Of Thirty Medical Innovations (2001)Physicians’ Views Of The Rela…Product innovation, product-market competition and persistent profitability in the U.S. pharmaceutical industry (1999)Product innovation, product-m…Do Important Drugs Reach the Market Sooner? (1994)Do Important Drugs Reach the …Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985). (1988)Pharmaceutical innovation by …Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry (1978)Estimating the Effects of Reg…Another look at the instrumental variable estimation of error-components models (1995)Initial conditions and moment restrictions in dynamic panel data models (1998)Econometric Analysis of Cross Section and Panel Data (2001)Fifty Years of Empirical Studies of Innovative Activity and Performance (2010)The productivity crisis in pharmaceutical R&D (2011)Why Working from Home Will Stick (2021)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The price of innovation: new estimates of drug development costs (2003)The black swan: the impact of the highly improbable (2007)THE WORLD MEDICINES SITUATION 2011 (2011)Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)The Strength of Weak Ties (1973)Social Capital in the Creation of Human Capital (1988)Exploration and Exploitation in Organizational Learning (1991)From Technological Inventions to New Products: A Systematic Review and Research Agenda of the Main Enabling Factors (2015)Knowledge diversity and coordination: The effect of intrafirm inventor task networks on absorption speed (2018)Networks and Innovation: Accounting for Structural and Institutional Sources of Recombination in Brokerage Triads (2018)The Theory of the Growth of the Firm (1995)Capitalism, Socialism and Democracy (1997)Markets, Firms, and the Process of Economic Development (1999)The Theory of Economic Development (2003)What makes a process a capability? Heuristics, strategy, and effective capture of opportunities (2007)Technical Change and Industrial Dynamics as Evolutionary Processes (2010)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)Economists' Views about Parameters, Values, and Policies: Survey Results in Labor and Public Economics (1998)Citation Frequency and the Value of Patented Inventions (1999)The Relationship Between Technology Availability And Health Care Spending (2003)Networks of knowledge: The distributed nature of medical innovation (2007)The value of health care – a matter of discussion in Germany (2007)Cost of innovation in the pharmaceutical industry (1991)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Incentives for orphan drug research and development in the United States (2008)The High Cost of Cancer Drugs and What We Can Do About It (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)The cost of biopharmaceutical R&D: is biotech different? (2007)Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)An overview of FDA-approved new molecular entities: 1827–2013 (2014)Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012 (2014)Changing R&D models in research-based pharmaceutical companies (2016)Links and Impacts: The Influence of Public Research on Industrial R&D (2002)Patents, Citations, and Innovations: A Window on the Knowledge Economy (2002)The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation (2015)Making technological innovation work for sustainable development (2016)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Innovation and Its Discontents: How Our Broken Patent System Is Endangering Innovation and Progress, and What to Do About It (2005)Innovation and Its Discontents (2011)Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents (2012)Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades (2012)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward (2015)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Importance of tacit knowledge in incremental innovation (2017)
this work references cited by second hop

References

  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2004Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry971 cited
  • 1999Product innovation, product-market competition and persistent profitability in the U.S. pharmaceutical industry705 cited
  • 1988Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).471 cited
  • 2007Economics of New Oncology Drug Development348 cited
  • 2010Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009329 cited
  • 2001Physicians’ Views Of The Relative Importance Of Thirty Medical Innovations289 cited
  • 2012Evergreening, patent challenges, and effective market life in pharmaceuticals262 cited
  • 2011What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?190 cited
  • 2011The impact of global and local cohesion on innovation in the pharmaceutical industry174 cited
  • 2006Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases162 cited
  • 1994Do Important Drugs Reach the Market Sooner?143 cited
  • 1978Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry131 cited
  • 2005Macro trends in pharmaceutical innovation112 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2005“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada109 cited
  • 2006The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003103 cited
  • Cited by

    No citing works inside the corpus for this window.